Autolus Therapeutics plc AUTL
1.09 USD -0.05 (-4.39%)
Regular-session close
1.12 +0.03 +2.76%
After hours · Nov 17, 5:50 PM ET
1.08 Day range 1.15
1.07 52-week range 2.58
- YTD
- -45.23%
- 1 year
- -18.66%
News
benzinga.com Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline Fonger-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), was presented today during…
globenewswire.com Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline In 15 patients evaluable for safety, obe-cel…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q3 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL raised its full-year AUCATZYL sales outlook after third-quarter revenue nearly doubled from a year earlier, as the company reported improved manufacturing margins…
benzinga.com Autolus Therapeutics Q3 2026 Earnings Call Transcript Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.
benzinga.com Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 30 percent increase over losses of…
globenewswire.com Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at…
globenewswire.com Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference LONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…benzinga.com Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Abstract 4498 – Oral PresentationTitle: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia…
globenewswire.com Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
globenewswire.com Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…benzinga.com HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.
seekingalpha.com Autolus Therapeutics: Key Questions For The Near Term Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing autoimmune pipeline catalysts. Q2 2026 saw product revenue rise to $45.7M, with net loss narrowing and…
globenewswire.com Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…
zacks.com All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
defenseworld.net Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
globenewswire.com Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q2 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year…
globenewswire.com Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…
globenewswire.com Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150…
seekingalpha.com Autolus Therapeutics: Navigating A Bumpy 2026 Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis…
zacks.com 3 Cancer Stocks to Watch as Oncology Innovation Accelerates Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
globenewswire.com Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
